We report on the identification of novel, nonsteroidal ligands that show pronounced subtype-selective differences in ligand binding and transcriptional potency or efficacy for the two estrogen receptor (ER) subtypes, ER␣ and ER␤. An aryl-substituted pyrazole is an ER␣ potency-selective agonist, showing higher binding affinity for ER␣ and 120-fold higher potency in stimulation of ER␣ vs. ER␤ in transactivation assays in cells. A tetrahydrochrysene (THC) has a 4-fold preferential binding affinity for ER␤; it is an agonist on ER␣, but a complete antagonist on ER␤. Intriguingly, the antagonist activity of THC is associated with the R,R-enantiomer (R,R-THC). The S,Senantiomer (S,S-THC) is an agonist on both ER␣ and ER␤ but has a 20-fold lower affinity for ER␤ than R,R-THC. This difference in binding affinity accounts for the full ER␤ antagonist activity of the THC racemate (a 1:1 mixture of R,R-THC and S,S-THC). These compounds should be useful in probing the conformational changes in these two ERs that are evoked by agonists and antagonists, and in evaluating the distinct roles that ER␤ and ER␣ may play in the diverse target tissues in which estrogens act. (Endocrinology 140: 800 -804, 1999) A S A MEDIATOR of the actions of estrogenic hormones, the estrogen receptor (ER) plays a central role in regulating a diverse array of normal physiological processes involved in the development and function of the reproductive system, as well as in many other aspects of health (cardiovascular, bone density, etc.), and estrogen pharmaceuticals have been developed to regulate these processes or their pathological counterparts, including infertility, breast cancer, and osteoporosis. The recent discovery of a second estrogen receptor, named estrogen receptor-␤ (ER␤) to distinguish it from the classical ER (now named ER␣), has opened new possibilities by which estrogen pharmaceuticals might exert tissue-and cell-selective activity (1-3). These ER subtypes have significantly different primary sequences in their ligand binding and transactivation domains, with ER␣ and ER␤ showing 56% amino acid identity in their hormone binding domain/activation function-2 region and only ca. 20% homology in their A/B domain/activation function-1 region. This suggests that these ER subtypes might bind some ligands with different affinity and that these ligands might also have different agonist or antagonist character mediated by the two receptors. Because ER␣ and ER␤ have some overlapping but also some different tissue distributions (2-4), differences in ligand interaction or activity with the two ERs could translate into important differences in their biological actions at the tissue level.
A S A MEDIATOR of the actions of estrogenic hormones, the estrogen receptor (ER) plays a central role in regulating a diverse array of normal physiological processes involved in the development and function of the reproductive system, as well as in many other aspects of health (cardiovascular, bone density, etc.), and estrogen pharmaceuticals have been developed to regulate these processes or their pathological counterparts, including infertility, breast cancer, and osteoporosis. The recent discovery of a second estrogen receptor, named estrogen receptor-␤ (ER␤) to distinguish it from the classical ER (now named ER␣), has opened new possibilities by which estrogen pharmaceuticals might exert tissue-and cell-selective activity (1) (2) (3) . These ER subtypes have significantly different primary sequences in their ligand binding and transactivation domains, with ER␣ and ER␤ showing 56% amino acid identity in their hormone binding domain/activation function-2 region and only ca. 20% homology in their A/B domain/activation function-1 region. This suggests that these ER subtypes might bind some ligands with different affinity and that these ligands might also have different agonist or antagonist character mediated by the two receptors. Because ER␣ and ER␤ have some overlapping but also some different tissue distributions (2-4), differences in ligand interaction or activity with the two ERs could translate into important differences in their biological actions at the tissue level.
To identify compounds that might have ER subtype-selective activity, we have examined some structurally diverse ER ligands and report on the identification of novel, nonsteroidal ligands that show pronounced subtype-selective differences in binding affinity and in transcriptional potency or efficacy. Notably, one is an ER␣ potency-selective agonist, and another is an agonist on ER␣ but a complete antagonist on ER␤. These compounds should be useful in structural studies on ER agonist and antagonist complexes, and in evaluating the distinct roles that ER␤ and ER␣ may play in the diverse target tissues in which estrogens act.
Materials and Methods

Chemicals, materials, and plasmid constructions
Cell culture media were purchased from Gibco BRL (Grand Island, NY). Calf serum was from Hyclone Laboratories, Inc. (Logan, UT) and FCS was from Atlanta Biologicals (Atlanta, GA).
14 C-Chloramphenicol (50 -60 Ci/mmol) and [ 3 H]E 2 were from DuPont NEN Research Products (Boston, MA). The expression vector for human ER␣ (pCMV5-hER) was constructed previously as described (5) . The expression vector pCMV5-ER␤ was constructed by inserting the full length complementary DNA encoding human ER␤ (530 residues, pNGV1-ER␤ (2) and including the additional 53 N-terminal amino acids as in GenBank accession number AF 051427, kindly provided by Sietse Mosselman of Organon, Oss, The Netherlands), into the BamHI site of pCMV5. The estrogen responsive reporter plasmids were (ERE) 3 -pS2-CAT, constructed as described previously (6), (ERE) 2 -TATA-CAT (5), C3-Ti-LUC, kindly provided by Donald McDonnell of Duke University, which contains Ϫ1030 to ϩ58 of the human complement C3 promoter fused to the firefly luciferase reporter gene (7) , and lactoferrin ERE-tk-CAT, kindly provided by Suzanne Fuqua of the University of Texas at San Antonio, which contains two copies of the nonconsensus lactoferrin ERE fused to the thymidine kinase promoter and CAT reporter gene. The plasmid pCH110 (Pharmacia, Piscataway, NJ) or pCMV␤ (CLONTECH Laboratories, Inc., Palo Alto, CA) which contains the ␤-galactosidase gene, was used as an internal control for transfection efficiency. The synthesis of compound 2 has been described (8, 9) . The synthesis of compounds 1, 3, and 4 will be described elsewhere (Fink, B. E., M. J. Meyers, and J.A. Katzenellenbogen, in preparation).
Cell culture and transient transfections
Human endometrial cancer (HEC-1) cells, Chinese hamster ovary (CHO) cells and HeLa cells were maintained in culture and transfected as described (5, 10, 11) . Transfection of HEC-1 cells in 60-mm dishes used 0.4 ml of a calcium phosphate precipitate containing 0.5 g of pCMV␤Gal as internal control, 2 g of the reporter gene plasmid, 100 ng of ER expression vector, and carrier DNA to a total of 5 g DNA. CAT or luciferase activity, normalized for the internal control ␤-galactosidase activity, was assayed as described (10, 11) .
Ligand binding assays
Ligand binding affinities were determined by competitive radiometric binding assays using 10 nm [ 3 H]E 2 as tracer, purified preparations of ER␣ (amino acids 304 -554) and ER␤ (256 -505) ligand binding domains expressed in Escherichia coli, and hydroxylapatite to adsorb bound receptor-ligand complex, as described previously (12) . Incubations were done at 0 C for 18 h.
Results
Compounds investigated
The structures of the compounds selected for analysis are shown in Fig. 1 . Compound 1 (pyrazole) is a triaryl-substituted pyrazole, which is a novel nonsteroidal ER ligand. Compound 2 (THC) is a cis-diethyl-substituted tetrahydrochrysene that was prepared as a racemate in the development of fluorescent ER ligands (8, 9) . Compounds 3 (R,R-THC) and 4 (S,S-THC) are the R,R-and S,S-enantiomers of compound 2, prepared by an enantioselective synthesis. Figure 2 shows the transcriptional activity of the pyrazole (compound 1) assayed in human endometrial cancer (HEC-1) cells with ER␣ and ER␤. Cells were transfected with an expression plasmid for ER␣ or ER␤ together with an estrogen-responsive reporter gene construct ((ERE) 3 -pS2-CAT), and were treated with increasing concentrations of the pyrazole, or with estradiol (E 2 ) for comparison. The pyrazole behaved as an ER␣ potency-selective agonist, showing a 120-fold higher potency in activating transcription via ER␣ than via ER␤. Similar ER␣ potency-selective character was observed with this compound in transcription assays in other cell types [Chinese hamster ovarian (CHO) cells, and HeLa cells], using the estrogen-responsive pS2 promoter, as well as the simple TATA promoter and the complement C3 promoter (data not presented).
Transcriptional activation with ER subtypeselective ligands
The transcriptional activity of compound 2 (THC) is shown in Fig. 3 . Of interest, compound 2 (THC) was a full ER␣ agonist, but showed no transcriptional activation of ER␤, and it fully suppressed E 2 -stimulated transcriptional activity via ER␤. Thus, this compound acts through ER␣ as an agonist, but through ER␤ as an antagonist. The potency of THC for ER␣ stimulation is approximately 200-fold less than E 2 (Fig. 3A) . Even at very high concentrations of THC, the compound showed no stimulation of ER␤ (Fig. 3B) , and a 100-fold excess of THC fully suppressed the E 2 stimulation of ER␤, with a 10-fold excess giving 50% suppression (Fig.  3B) . Thus, the THC appears to be more potent as an ER␤ antagonist than it is as an ER␣ agonist, which may be explained by its preferential binding affinity for ER␤ (see below, Table 1 ).
Because the enantiomers in a racemate (a 1:1 mixture of enantiomers) often have different biological activities (13), we synthesized the individual R,R-and S,S-enantiomers of the THC and examined their separate activities through ER␣ and ER␤. Intriguingly, as shown in Fig. 4 , the ER␤ selective antagonist activity of THC resides completely in the R,Renantiomer of THC (compound 3). Although R,R-THC was an agonist on ER␣, it showed no stimulation of ER␤, and it fully suppressed E 2 activation of ER␤. By contrast, the S,Senantiomer (compound 4), which was an agonist on ER␣, was also a nearly full agonist on ER␤. It is of note that the R,R-enantiomer of THC gave a profile for suppression of E 2 stimulation through ER␤ similar to that of the THC racemate, which is consistent with the much higher affinity of the R,R-THC enantiomer for ER␤ than that of the S,S-enantiomer (see below, Table 1 ).
The activity of compounds 2-4 shown in Figs. 3 and 4 was also observed in all other cell and promoter contexts examined. One example is presented in Fig. 5 , using the complement C3 promoter, an estrogen-responsive promoter which contains nonconsensus EREs, and another is shown in Fig. 6 using the nonconsensus lactoferrin estrogen-responsive element and the heterologous thymidine kinase promoter. THC is again seen to be an ER␤ selective antagonist ligand. In addition, pyrazole is seen to be an ER␣ potency-selective agonist ligand (Fig. 6 ). Other cell and promoter contexts examined but not shown, which gave similar transactivation profiles to those presented, included CHO cells and a simple promoter with consensus EREs (2ERE-TATA-CAT) and HEC-1 cells with nonconsensus EREs from the pS2 and cathepsin D genes linked to the thymidine kinase promoter.
Binding affinities of ER subtype-selective ligands
The relative binding affinities and K i values of compounds 1-4 for ER␣ and ER␤ are shown in Table 1 . For comparison, the values are also given for the antiestrogens hydroxytamoxifen and ICI182,780. The pyrazole compound, which was an ER␣ potency-selective agonist (Fig. 2) , showed higher affinity for ER␣, as might have been predicted. The 9-fold difference in receptor binding affinity, however, does not account fully for the 120-fold difference in transactivation potency on the two ER subtypes.
The binding affinities of the three THC compounds reflect closely their ER subtype selective potencies. The R,R-enantiomer (compound 3) has a 3-fold preferential binding for ER␤, consistent with the higher potency of this compound as an ER␤ antagonist than as an ER␣ agonist. The S,S-enantiomer (compound 4) has lower overall affinity, showing little preference for either subtype, which matches its equivalent potency as an agonist on both ER␣ and ER␤. The relative affinities of compounds 3 and 4 for the two ERs are nicely 4 . Transcription activation by ER␣ and ER␤ in response to the R, R-THC (compound 3) and the S, S-THC (compound 4). Transfection assays were conducted in HEC-1 cells using the (ERE) 3 -pS2-CAT reporter as described in the legend of Fig. 2 . B, The antagonist activity of both compounds on ER␤ was assayed in the presence of 1 nM E 2 .
FIG. 5 . Transcription activation by ER␣ and ER␤ in response to the THC (compound 2) through the complement C3 promoter. Transfection assays were conducted in HEC-1 cells as described in the legend of Fig. 2 , except that the complement C3 promoter was used (Ϫ1030 to ϩ58 of C3 promoter fused to the luciferase reporter gene). B, The antagonist activity of THC on ER␤ was assayed in the presence of 1 nM E 2 . Luciferase activity was normalized for ␤-galactosidase activity from a cotransfected internal control plasmid. Values are the mean Ϯ SD from three separate experiments and are expressed as a percent of the ER␣ or ER␤ response with 1 nM E 2 .
reflected in the racemate (compound 2), whose binding is simply the average of that of the two enantiomers. The two well known antiestrogens, hydroxytamoxifen and ICI182,780, show somewhat higher affinities for ER␣ than for ER␤.
Discussion
In this report, we describe novel ligands for ER␣ and ER␤, a pyrazole compound (compound 1) that is a 120-fold potency selective agonist for ER␣, and THC compounds (THC and R,R-THC) that are agonists via ER␣ but full antagonists via ER␤. The latter two compounds differ from antiestrogenic compounds such as tamoxifen and raloxifene, that are full antagonists on ER␤ but usually have only minimal agonist activity on ER␣ when assayed in systems similar to those used here (4, 10, 11, (15) (16) (17) . For example, in HEC-1 cells hydroxytamoxifen has 25% the agonist activity of estradiol through ER␣, but is a pure antagonist through ER␤ (11, 15) . By contrast, THC and R,R-THC are nearly full agonists on ER␣.
Others have reported on compounds that show differences in their binding affinity for ER␣ and ER␤ (4). ER␣ affinity selectivities up to 5 have been found for certain substituted estrogens, especially those with 17␣ substituents. The highest ER␤ affinity selectivities of approximately 7 have been reported for certain nonsteroidal phytoestrogens, such as genistein. When the difference in relative binding affinity of the tracers used in these studies (16␣ -[ 125 I] iodoestradiol in Ref. 4 and [ 3 H] estradiol, this study) for ER␣ and ER␤ is taken into consideration, THC and the R,R-enantiomer show equally high ER␤ affinity selectivities.
The relative potency of R,R-THC (compound 3) in the ER␣ and ER␤ transcription assays correlates rather well with its relative affinity in the ligand binding assays: It has a higher affinity for ER␤, which is consistent with its greater potency as an ER␤ antagonist than as an ER␣ agonist. The S,S-enantiomer (compound 4) has both lower affinity and less selectivity in its binding to ER␣ and ER␤, which is consistent with its equivalent potency as an agonist on both ER subtypes. Interestingly, the racemate (compound 2), which consists of an equal mixture of the R,R-and S,S-enantiomers, behaves much the same as the R,R-enantiomer in both binding and transactivation assays. As expected, the affinity of the racemate for both ER subtypes is the average of that of the two enantiomers. Because the antagonistic R,R-enantiomer has a 20-fold higher affinity for ER␤ compared with that of the agonistic S,S-enantiomer (Table 1) , the antagonist character of the R,R-enantiomer dominates the agonist character of the S,S-enantiomer, so that the racemate is also a very effective antagonist on ER␤.
There is, however, not always a direct correlation between binding affinity and transcriptional potency. The pyrazole (compound 1) has only moderately lower affinity for ER␣ and only 5-fold lower affinity for ER␤ than does E 2 , yet its potency as an agonist on both subtypes is considerably less than that of E 2 (Fig. 2) . Its higher affinity for ER␣ vs. ER␤, however, is reflected in its ER␣ agonist potency selectivity, although its 120-fold potency selectivity in the transcription assay is considerably greater than its 9-fold affinity selectivity. This suggests that factors beyond ligand-receptor interaction, such as receptor-coactivator interactions, are likely to be important determinants of transcriptional potency (18) . In addition, the role of activation functions 1 and 2 (AF1 and AF2) in mediating the activity of the pyrazole and THC compounds as agonists and antagonists through ER␣ and ER␤ remains an aspect of importance. This is a complex issue because we and others find that the importance of AF1 and AF2 in ER␣ and ER␤ with estradiol and other ligands depends greatly on both the cell background and promoter context (11, 15, 19) , as we observe also with compounds 1-4.
Recently reported crystal structures of ER␣ complexed with E 2 or the antiestrogen raloxifene reveal that the position of helix-12, the activation function 2 activation helix, is very different with these two ligands, being packed into the ligand binding pocket in the complex with agonist, but displaced and extended in the antagonist complex (20) . This conformational change was suggested to be an important molecular determinant in mediating the agonist vs. antagonist activity of the bound ligand (20) . In this regard, compound 3, the R,R-enantiomer of THC, should be of considerable interest in probing the conformational correlates of agonist vs. antagonist activity in the two ER subtypes, as one would predict that its complex with ER␣ would be in the agonist conformation, whereas its complex with ER␤ would be in the antagonist conformation.
These compounds should also be useful as pharmacological probes to elucidate the biological roles played by ER␤ vs. ER␣. For example, the ER␤-selective antagonist (the R,R-THC, compound 3) could be used to identify ER␤-mediated activities in both wild-type and ER␣-knockout animals by their selective suppression by this ligand. Likewise, the ER␣ potency-selective agonist (pyrazole, compound 1), at an appropriate dose, could be used to selectively activate ER␣ in cells or tissues that contain both receptor subtypes. FIG. 6 . Transcription activation by ER␣ and ER␤ in response to the pyrazole (compound 1) and R,R-THC (compound 3) monitored in transfection assays in HEC-1 cells using the lactoferrin nonconsensus ERE fused to the thymidine kinase promoter and CAT reporter gene. CAT activity was normalized for ␤-galactosidase activity from a cotransfected internal control plasmid. Values are the mean Ϯ SD from three experiments and are expressed as a percent of the ER␣ or ER␤ response with 10 nM E 2 .
